A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

Completed

Looking for future studies?

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Malignant Melanoma Melanoma Movement Disorders Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Nervous System Diseases Neurodegenerative Diseases Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Parkinson Disease Parkinsonian Disorders Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Synucleinopathies

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Confirmed diagnosis Parkinson's disease Patient able and willing to give informed consent Patient must not be taking any investigational drug at the time of enrollment

Exclusion criteria

unconfirmed, undocumented Parkinson's disease unable to give consent taking any investigational product

Sponsors and collaborators

Lead sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Industry

Registry information

Official study title

A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients

Important dates

Study start: 2003
Study completion: 2003
First posted: Sep 20, 2005
Registry last updated: Oct 18, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed